Clinical Trial

Semaglutide for Post-Smoking Cessation Weight Management

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-07; most recent amendment 2026-02-06.
Status change: Not Yet Recruiting → Recruiting 2024-05-14
Trial Details
NCT Number NCT06173778
Lead Sponsor The University of Texas Health Science Center, Houston
Conditions Obesity, Overweight, Cigarette Smoking
Enrollment 197 participants
Start Date 2024-04-23
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11